tm
Seeing Is Believing
tm
Seeing Is Believing
TRVI is currently covered by 7 analysts with an average price target of $20.62. This is a potential upside of $10.15 (96.94%) from yesterday's end of day stock price of $10.47.
Trevi Therapeutics's activity chart (see below) currently has 29 price targets and 48 ratings on display. The stock rating distribution of TRVI is 100% BUY.
Analysts average stock forecasts to be materialized ratio is 52.34% with an average time for these price targets to be met of 770.5 days.
Highest price target for TRVI is $24, Lowest price target is $12.5, average price target is $19.79.
Most recent stock forecast was given by BRANDON FOLKES from HC WAINWRIGHT on 09-Jan-2026. First documented stock forecast 03-Jun-2019.
Currently out of the existing stock ratings of TRVI, 19 are a BUY (100%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 13-Jun-2024
$21
$10.53 (100.57%)
$21
22 days ago
(09-Jan-2026)
1/3 (33.33%)
$9.82 (87.84%)
358
Buy Since 16-Dec-2024
$19
$8.53 (81.47%)
$19
23 days ago
(08-Jan-2026)
0/7 (0%)
$7.79 (69.49%)
Buy Since 03-Jun-2019
$18
$7.53 (71.92%)
$12
1 months 12 days ago
(19-Dec-2025)
2/4 (50%)
$5.81 (47.66%)
1092
Buy Since 25-May-2022
$24
$13.53 (129.23%)
$20
2 months 17 days ago
(14-Nov-2025)
2/4 (50%)
$12.54 (109.42%)
1221
Buy Since 03-Jun-2019
$24
$13.53 (129.23%)
$24
8 months 11 days ago
(20-May-2025)
11/16 (68.75%)
$17.53 (270.94%)
653
What is TRVI (Trevi Therapeutics) average time for price targets to be met?
Which analyst has the current highest performing score on TRVI (Trevi Therapeutics) with a proven track record?
Which analyst has the current lower performing score on TRVI (Trevi Therapeutics) with a proven track record?
Which analyst has the most public recommendations on TRVI (Trevi Therapeutics)?
Which analyst is the currently most bullish on TRVI (Trevi Therapeutics)?
Which analyst is the currently most reserved on TRVI (Trevi Therapeutics)?
